COVID-OUT Media Resources

Parsemus Foundation Press Information

About the Parsemus Foundation

The Parsemus Foundation works to create meaningful improvements in human and animal health and welfare by advancing innovative and neglected medical research. The foundation supports proof-of-concept studies and then seeks to raise awareness of results, to ensure that they change treatment practice rather than disappear into the scientific literature. Many of the studies the foundation supports involve low-cost approaches that are not under patent, and are thus unlikely to be pursued by pharmaceutical companies due to limited profit potential.

Latest News

COVID-OUT Clinical Trial Results Announced!

The key finding: if started within 4 days of COVID symptoms, the widely available diabetes drug metformin reduced serious outcomes by more than half.

Background: The COVID-OUT clinical trial was aimed at understanding if safe, commonly available medications may treat COVID-19 symptoms and those of long COVID. The study examined the medications metformin, ivermectin, and fluvoxamine, which are known to decrease inflammatory proteins (cytokines) in the body. They also appear to possibly stop the proteins inside cells that help viruses reproduce and spread. This rigorous randomized, controlled clinical trial was conducted by the University of Minnesota under the direction of Dr. Carolyn Bramante. 

Funders: The Parsemus Foundation provided pilot funding and enrollment support to the University of Minnesota. Additional major funders include the University of Minnesota Clinical Translational Science Institute, the Rainwater Foundation, FastGrants, and UnitedHealth Group Research and Development.

Additional Information:

Video and Audio Files, and Transcripts

Video clips - English language

Elaine Lissner COVID-Out video image

Intriguing clues, then randomized trial

Elaine Lissner, Trustee
Parsemus Foundation

Elaine Lissner COVID-Out video image

Inclusiveness and representation

Elaine Lissner, Trustee
Parsemus Foundation

Elaine Lissner COVID-Out video image

Reducing barriers to quick use

Elaine Lissner, Trustee
Parsemus Foundation

Elaine Lissner COVID-Out video image

Lessons for the future

Elaine Lissner, Trustee
Parsemus Foundation

Transcripts for all media files on this page

Elaine Lissner COVID-Out video image

A Word document of all transcripts

Elaine Lissner, Trustee
Parsemus Foundation

Video clips - Spanish language

Elaine Lissner COVID-Out video image

Disponibilidad en América Latina

Elaine Lissner, Fideicomisaria
Fundación Parsemus

Audio clips - English language

Elaine Lissner COVID-Out video image

It’s natural that people will be cautious

Elaine Lissner, Trustee
Parsemus Foundation

Elaine Lissner COVID-Out video image

Many people will ask

Elaine Lissner, Trustee
Parsemus Foundation

Elaine Lissner COVID-Out video image

The study tested three medications head to head

Elaine Lissner, Trustee
Parsemus Foundation

Audio clips - Spanish language

Elaine Lissner COVID-Out video image

Se trataba de justicia global

Elaine Lissner, Fideicomisaria
Fundación Parsemus

Audio clips - Portuguese language

Elaine Lissner COVID-Out video image

Uma solução disponível para todos

Elaine Lissner, Fiduciária
Parsemus Foundation

Elaine Lissner COVID-Out video image

Algo que toda família poderia manter à mão

Elaine Lissner, Fiduciária
Parsemus Foundation

We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today